Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years

Exposure to non-corticosteroid treatments in adult primary immune thrombocytopenia before the chronic phase in the era of thrombopoietin receptor agonists in France. A nationwide population-based study

(2015) Guillaume Moulis et al.   AUTOIMMUNITY REVIEWS

High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial

(2015) Y. Wei et al.   BLOOD

Management of immune thrombocytopenia in adults: a population-based analysis of the French hospital discharge database from 2009 to 2012

(2015) Marc Michel et al.   BRITISH JOURNAL OF HAEMATOLOGY

Can Immune Thrombocytopenia Be Cured with Medical Therapy?

(2015) Eline Prak et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study

(2014) Matthieu Mahévas et al.   BRITISH JOURNAL OF HAEMATOLOGY

Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia

(2013) S. Boyle et al.   BLOOD

Pathophysiology and management of primary immune thrombocytopenia

(2013) Hirokazu Kashiwagi et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment

(2012) W. Ghanima et al.   BLOOD

Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia

(2012) V. L. Patel et al.   BLOOD

Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years

(2012) N. Vianelli et al.   HAEMATOLOGICA

Single course of high dose dexamethasone is more effective than conventional prednisolone therapy in the treatment of primary newly diagnosed immune thrombocytopenia

(2012) Mohammad Mashhadi et al.   DARU-Journal of Pharmaceutical Sciences

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

(2011) C. Neunert et al.   BLOOD

Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study

(2010) Gregory Cheng et al.   LANCET

Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia

(2010) David J. Kuter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

(2009) K. R. Carson et al.   BLOOD

International consensus report on the investigation and management of primary immune thrombocytopenia

(2009) D. Provan et al.   BLOOD

Chronic Idiopathic Thrombocytopenic Purpura: Mechanisms of Pathogenesis

(2009) T. Gernsheimer   ONCOLOGIST

CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care setting

(2008) Teresa C. Horan et al.   AMERICAN JOURNAL OF INFECTION CONTROL

Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study

(2008) B. Godeau et al.   BLOOD

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

(2008) F. Rodeghiero et al.   BLOOD

Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results

(2008) Marta Medeot et al.   EUROPEAN JOURNAL OF HAEMATOLOGY